Loading organizations...
Animol Discovery is a Boston, Massachusetts-based biopharmaceutical company that utilizes DNA-encoded libraries and machine learning to discover novel small molecule therapeutics for companion and farm animals. The organization develops a proprietary pipeline of active pharmaceutical ingredients targeting various veterinary medical needs, ranging from anti-parasitics to complex chronic diseases. Operating with fewer than 25 employees and generating under $5 million in estimated annual revenue, the enterprise successfully secured $34.0 million in Series B financing in 2022. This specific funding round was led by Novalis Lifesciences, with additional backing from venture capital firms Anterra Capital and Finistere Ventures. The company's leadership team includes former Bayer AG executives Douglas Hutchens as Chief Scientific Officer and Marijn Dekkers on the board of directors. Animol Discovery was officially founded in 2020 by scientific co-founder Andrew Calabrese and partner Philip Trajanov.
Animol Discovery has raised $40.0M across 2 funding rounds.
Animol Discovery has raised $40.0M in total across 2 funding rounds.
Animol Discovery has raised $40.0M in total across 2 funding rounds.
Animol Discovery's investors include Marijn Dekkers, Anterra Capital, F-Prime Capital Partners, Finistere Ventures.
Animol Discovery is a biopharmaceutical company developing novel small molecule pharmaceuticals for unmet needs in veterinary medicine, targeting both companion and farm animals.[1][2][3] It builds a proprietary pipeline of active pharmaceutical ingredients (APIs) addressing conditions like anti-parasitics and chronic diseases, using a platform combining genomics analysis, DNA-encoded libraries (DELs), AI/machine learning, and computational chemistry to accelerate discovery of safer, more effective drugs.[1][2][3][4] The company serves veterinary patients by solving gaps in current treatments, where existing drugs fall short in efficacy or safety, and recently raised $34 million in Series B financing to advance its pipeline through clinical development.[2]
Animol Discovery was co-founded by Andrew Calabrese, Ph.D., a scientific expert with extensive experience in biotech startups across human health, animal health, and crop protection.[3] Calabrese, previously at Pfizer and Celgene, invented drug candidates like Cligcosiban™ (in late-stage human trials) and led animal health products such as Aviax™ (anticoccidial) and TreoAce™ (endectocide commercialized in under three years).[3] The idea emerged from recognizing unmet veterinary needs and leveraging Calabrese's R&D expertise from concept to commercialization, building a team of animal health industry veterans.[3] Early momentum includes building a proprietary pipeline and securing Series B funding led by Novalis Lifesciences, with participation from Finistere Ventures and Anterra Capital.[2]
Animol Discovery stands out in veterinary drug discovery through:
Animol Discovery rides the convergence of AI, DELs, and computational tools transforming drug discovery, particularly in underserved veterinary markets where human pharma adaptations often underperform.[1][4] Timing aligns with rising demand for animal health innovations amid growing pet ownership, sustainable farming, and regulatory pushes for better livestock welfare, amplifying market forces like biotech funding in agtech/vetmed.[2] It influences the ecosystem by pioneering animal-specific platforms, potentially lowering barriers for novel APIs and inspiring similar tech stacks in biotech, bridging gaps between human and veterinary R&D.[3][5]
Animol Discovery is poised to advance its pipeline into clinical trials with Series B capital, targeting breakthroughs in anti-parasitics and chronic veterinary conditions.[2] Trends like AI-driven screening and expanded DEL applications will accelerate its momentum, while partnerships could fast-track commercialization.[1][4] Its influence may grow by setting standards for tech-enabled vet pharma, potentially capturing share in a market hungry for tailored, effective treatments—ultimately delivering on its mission to innovate until every animal is well.[1]
Animol Discovery has raised $40.0M across 2 funding rounds. Most recently, it raised $34.0M Series B in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2022 | $34M Series B | Marijn Dekkers | Anterra Capital, F Prime Capital, Finistere Ventures | Announced |
| Dec 1, 2019 | $6M Series A | — | Anterra Capital, F Prime Capital | Announced |